158 related articles for article (PubMed ID: 35251480)
21. Low concentration of quercetin antagonizes the cytotoxic effects of anti-neoplastic drugs in ovarian cancer.
Li N; Sun C; Zhou B; Xing H; Ma D; Chen G; Weng D
PLoS One; 2014; 9(7):e100314. PubMed ID: 24999622
[TBL] [Abstract][Full Text] [Related]
22. Ghrelin enhances cisplatin sensitivity in HO-8910 PM human ovarian cancer cells.
Leng Y; Zhao C; Yan G; Xu S; Yang Y; Gong T; Li X; Li C
J Ovarian Res; 2021 Nov; 14(1):162. PubMed ID: 34789301
[TBL] [Abstract][Full Text] [Related]
23. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract][Full Text] [Related]
24. Reactive oxygen species-mediated synergistic and preferential induction of cell death and reduction of clonogenic resistance in breast cancer cells by combined cisplatin and FK228.
Pluchino LA; Choudhary S; Wang HC
Cancer Lett; 2016 Oct; 381(1):124-32. PubMed ID: 27477899
[TBL] [Abstract][Full Text] [Related]
25. The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells.
Lin YH; Chen BY; Lai WT; Wu SF; Guh JH; Cheng AL; Hsu LC
Naunyn Schmiedebergs Arch Pharmacol; 2015 Jan; 388(1):19-31. PubMed ID: 25164962
[TBL] [Abstract][Full Text] [Related]
26. Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action.
Ayyagari VN; Brard L
BMC Cancer; 2014 Feb; 14():61. PubMed ID: 24495391
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
28. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
Chen XX; Xie FF; Zhu XJ; Lin F; Pan SS; Gong LH; Qiu JG; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Shi Z; Yan XJ
Oncotarget; 2015 Jun; 6(17):14926-39. PubMed ID: 25962959
[TBL] [Abstract][Full Text] [Related]
29. Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors.
Pandey N; Tyagi G; Kaur P; Pradhan S; Rajam MV; Srivastava T
Cell Physiol Biochem; 2020 Aug; 54(4):748-766. PubMed ID: 32809300
[TBL] [Abstract][Full Text] [Related]
30. Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.
Nawrocki ST; Kelly KR; Smith PG; Espitia CM; Possemato A; Beausoleil SA; Milhollen M; Blakemore S; Thomas M; Berger A; Carew JS
Clin Cancer Res; 2013 Jul; 19(13):3577-90. PubMed ID: 23633453
[TBL] [Abstract][Full Text] [Related]
31. Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo.
Zhou B; Xia M; Wang B; Thapa N; Gan L; Sun C; Guo E; Huang J; Lu Y; Cai H
J Ovarian Res; 2019 Nov; 12(1):107. PubMed ID: 31703731
[TBL] [Abstract][Full Text] [Related]
32. JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells.
Zhao Z; Wang J; Tang J; Liu X; Zhong Q; Wang F; Hu W; Yuan Z; Nie C; Wei Y
Biochem J; 2012 Jun; 444(2):291-301. PubMed ID: 22394200
[TBL] [Abstract][Full Text] [Related]
33. DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.
Meng Y; Chen CW; Yung MMH; Sun W; Sun J; Li Z; Li J; Li Z; Zhou W; Liu SS; Cheung ANY; Ngan HYS; Braisted JC; Kai Y; Peng W; Tzatsos A; Li Y; Dai Z; Zheng W; Chan DW; Zhu W
Cancer Lett; 2018 Aug; 428():104-116. PubMed ID: 29704517
[TBL] [Abstract][Full Text] [Related]
34. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
35. Glaucocalyxin A impairs tumor growth via amplification of the ATF4/CHOP/CHAC1 cascade in human oral squamous cell carcinoma.
Wang X; He MJ; Chen XJ; Bai YT; Zhou G
J Ethnopharmacol; 2022 May; 290():115100. PubMed ID: 35151835
[TBL] [Abstract][Full Text] [Related]
36. Sequenced Combinations of Cisplatin and Selected Phytochemicals towards Overcoming Drug Resistance in Ovarian Tumour Models.
Althurwi SI; Yu JQ; Beale P; Huq F
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053689
[TBL] [Abstract][Full Text] [Related]
37. Oridonin Suppresses Proliferation of Human Ovarian Cancer Cells via Blockage of mTOR Signaling.
Xia R; Chen SX; Qin Q; Chen Y; Zhang WW; Zhu RR; Deng AM
Asian Pac J Cancer Prev; 2016; 17(2):667-71. PubMed ID: 26925661
[TBL] [Abstract][Full Text] [Related]
38. Glaucocalyxin A exerts anticancer effect on osteosarcoma by inhibiting GLI1 nuclear translocation via regulating PI3K/Akt pathway.
Zhu J; Sun Y; Lu Y; Jiang X; Ma B; Yu L; Zhang J; Dong X; Zhang Q
Cell Death Dis; 2018 Jun; 9(6):708. PubMed ID: 29899333
[TBL] [Abstract][Full Text] [Related]
39. PD98059 impairs the cisplatin-resistance of ovarian cancer cells by suppressing ERK pathway and epithelial mesenchymal transition process.
Hou L; Hou X; Wang L; Li Z; Xin B; Chen J; Gao X; Mu H
Cancer Biomark; 2017 Dec; 21(1):187-194. PubMed ID: 29103028
[TBL] [Abstract][Full Text] [Related]
40. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F
Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]